Organon & Co. (OGN) Competitors

Organon & Co. (NYSE:OGN) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, risk, dividends, earnings and valuation.

Which has higher earnings and valuation, OGN or GMAB?

Genmab A/S has lower revenue, but higher earnings than Organon & Co.. Organon & Co. is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.40B	0.62	$864M	$3.33	4.65
Genmab A/S	$3.12B	4.72	$1.14B	$1.74	12.80

Do analysts recommend OGN or GMAB?

Organon & Co. currently has a consensus target price of $20.80, indicating a potential upside of 34.19%. Genmab A/S has a consensus target price of $42.17, indicating a potential upside of 89.30%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts clearly believe Genmab A/S is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Genmab A/S	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

Do institutionals & insiders hold more shares of OGN or GMAB?

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 1.4% of Organon & Co. shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Is OGN or GMAB more profitable?

Genmab A/S has a net margin of 36.30% compared to Organon & Co.'s net margin of 13.49%. Organon & Co.'s return on equity of 431.62% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	13.49%	431.62%	8.03%
Genmab A/S	36.30%	16.78%	13.79%

Which has more volatility and risk, OGN or GMAB?

Organon & Co. has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Does the media favor OGN or GMAB?

In the previous week, Organon & Co. had 1 more articles in the media than Genmab A/S. MarketBeat recorded 19 mentions for Organon & Co. and 18 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.00 beat Organon & Co.'s score of 0.42 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	7 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Genmab A/S	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer OGN or GMAB?

Genmab A/S received 146 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 62.84% of users gave Genmab A/S an outperform vote while only 33.96% of users gave Organon & Co. an outperform vote.

Company	Underperform	Outperform
Organon & Co.	Outperform Votes 18 33.96%	Underperform Votes 35 66.04%
Genmab A/S	Outperform Votes 164 62.84%	Underperform Votes 97 37.16%

Summary

Genmab A/S beats Organon & Co. on 13 of the 18 factors compared between the two stocks.